Bookmark
Forward
QuickView for Gadofosveset trisodium (compound)
PubChem
| Name: | gadofosveset trisodium |
|---|---|
| PubChem Compound ID: | 158440 |
| Molecular formula: | C33H40GdN3Na3O15P |
| Molecular weight: | 975.875 g/mol |
| Synonyms: |
Gadolinate(3-), (((4R)-4-(bis((carboxy-kappaO)methyl)amino-kappaN)-6,9-bis((carboxy-kappaO)methyl)-1-((4,4-diphenylcyclohexyl)oxy)-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-oic acid-kappaN6,kappaN9,kappaO11) 1-oxidato(6-))-, trisodium; Gadofosveset trisodium; Gadofosveset trisodium [USAN]; MS 32520; 193901-90-5
|
DrugBank
Identification
| Name: | gadofosveset trisodium |
|---|---|
| Name (isomeric): | DB06705 |
| Drug Type: | small molecule |
| Brand: | Vasovist |
| CAS number: | 193901-90-5 |
Pharmacology
| Indication: | Gadofosveset trisodium is used as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. |
|---|---|
| Mechanism of Action: |
Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons resulting in an increase in signal intensity (brightness...
show more » |
| Biotransformation: | Gadofosveset does not undergo measurable metabolism. |
| Route of elimination: | Gadofosveset is eliminated primarily in the urine with approximately 83.5% of an injected dose excreted in the urine over 14 days. Ninety-four percent (94%) of urinary excretion occurs in the first 72 hours. A small portion of gadofosveset dose is recovered in feces (approximately 4.7%). |
| Clearance: | 6.57 ± 0.97 mL/h/kg following the administration of 0.03 mmol/kg. |
| Toxicity: | Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m²). |
Interactions
| Drug interaction: |
|
|---|
Carriers
